Ventana Issues Clarifying Press Release

  Ventana Biotech Inc. ("Ventana") (PINK SHEETS: VNTA), a biotechnology company developing an appetite-suppressing and stress reducing chewing gum, clarified today information disseminated in previous press releases regarding becoming a fully reporting OTCBB issuer.

The Company has retained legal counsel and are taking the steps to become a fully reporting OTCBB issuer, the Company wants to make it clear that it is still listed on the Pink Sheet quotation system and that obtaining a OTCBB status requires a filing of a Registration Statement which the company expects to file before the end of the year.

About Ventana Biotech Inc

Ventana is positioning itself as the leading bioscience company in the development and commercial licensure of novel therapeutic anti-obesity drug treatment. The company leverages cutting-edge research collaborations to achieve breakthroughs in innovative anti-obesity treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

FORWARD-LOOKING STATEMENTS:

Statements about Ventana's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. Ventana's actual results could differ materially from expected results. Ventana does not undertake any obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this objective; Ventana will appropriately inform the public.

Contacts: Ventana Biotech Inc Janne Christensen, CEO BCB 1 Bachstrasse Butschwil CH-9606 Switzerland + 41-44-732-60-59